Savara Announces Participation in Upcoming Healthcare Investor Conferences

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.

Guggenheim SMID Cap Biotech Conference, February 5-6, 2025 Fireside Chat: February 5th, 10:00am ET/7:00am PT

Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Fireside Chat: February 11th, 8:00am ET/5:00am PT

The live webcasts and subsequent replays will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma and LinkedIn.

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129351153/en/

Media and Investor Relations Contact Savara Inc. Temre Johnson, Executive Director, Corporate Affairs [e-mail]